Dr. Victor Adepoju | Global Health | Excellence in Research

Director, Infectious diseases and Research at Jhpiego, Nigeria.

Dr. Victor Adepoju is a distinguished public health physician, researcher, and strategic information expert with over 14 years of experience managing large-scale global health programs across various income settings. As a Portfolio Director at Jhpiego, an affiliate of Johns Hopkins University, he leads multi-million-dollar projects in infectious diseases, maternal health, and immunization. With expertise in TB, HIV, viral hepatitis, and health systems strengthening, he has over 70 peer-reviewed publications and has contributed to WHO guidelines. Fluent in English and Yoruba, he is a global health leader driving universal health coverage and healthcare innovation.

Professional Profile:

Google Scholar

Education & Experience 🎓💼

MBChB (Bachelor of Medicine & Surgery) – Obafemi Awolowo University 🏥
MSc (International Management of Health Systems) – University of Liverpool 🌍
Master Certificate in Healthcare Leadership – Cornell University 🎯
PhD (Public Health) – Crown International University 🏆
Portfolio Director, Jhpiego (Johns Hopkins University Affiliate) (2021–Present) 🌍
Over 14 years in global health, working with USAID, Global Fund, GAVI, and UNITAID 💡

Professional Development 📈🩺

Dr. Adepoju is a seasoned expert in global health implementation, policy, and research. He has designed and led health interventions for TB, HIV, maternal and child health, and neglected tropical diseases, securing over $100 million in funding. His work in operational research, health systems strengthening, and digital health innovations has shaped policies globally. With experience in capacity building, health financing, and universal health coverage, he has collaborated with Ministries of Health, civil society, and donors. A thought leader in market shaping, he drives equitable access to healthcare solutions for vulnerable populations worldwide.

Research Focus 🔬📚

Dr. Adepoju’s research spans infectious diseases (HIV, TB, viral hepatitis, COVID-19, and mpox), neglected tropical diseases, and maternal, newborn, and child health (MNCH). His expertise extends to universal health coverage, health systems strengthening, and innovative diagnostics. He is a leader in market shaping, improving access to essential medicines and vaccines in low- and middle-income countries (LMICs). His work also includes health financing, strategic information, and public-private partnerships. His contributions to implementation science have shaped WHO policies and national health guidelines across multiple regions.

Awards & Honors 🏅🎖

An Excellence in Global Health Leadership Award 🌍🏆
USAID/Global Fund Project Recognition Award 🏥💡
Jhpiego Outstanding Leadership Award 🏅
Best Public Health Research Paper Award 📖
UNITAID Health Innovation Award 💉
Certificate of Excellence in Health Systems Strengthening 🏆
Recognition for Policy Contribution to WHO Guidelines 📜

Publication Top Notes

📄 Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 402 (10397), 203-234 📅 2023 🔍 Cited by: 1972

📄 Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories, 1990–2021 – The Lancet 403 (10440), 2133-2161 📅 2024 🔍 Cited by: 566

📄 Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2100-2132 📅 2024 🔍 Cited by: 530

📄 Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic – The Lancet 403 (10440), 1989-2056 📅 2024 🔍 Cited by: 321

📄 The burden of bacterial antimicrobial resistance in the WHO African region in 2019: a cross-country systematic analysis – The Lancet Global Health 12 (2), e201-e216 📅 2024 🔍 Cited by: 112

📄 Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021 – The Lancet 403 (10440), 2057-2099 📅 2024 🔍 Cited by: 97

📄 Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021 – The Lancet Infectious Diseases 24 (9), 974-1002 📅 2024 🔍 Cited by: 60

📄 Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the Global Burden of Disease Study 2019 – EClinicalMedicine 64 📅 2023 🔍 Cited by: 54

📄 Prevalence of rifampicin-resistant tuberculosis and associated factors among presumptive tuberculosis patients in a secondary referral hospital in Lagos, Nigeria – African Health Sciences 18 (3), 472-478 📅 2018 🔍 Cited by: 48

📄 Childhood tuberculosis in Nigeria: disease presentation and treatment outcomes – Health Services Insights 11, 1178632918757490 📅 2018 🔍 Cited by: 40

Victor Adepoju | Global Health | Excellence in Research